These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35232962)

  • 1. Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF
    Smith LK; Parmenter T; Kleinschmidt M; Kusnadi EP; Kang J; Martin CA; Lau P; Patel R; Lorent J; Papadopoli D; Trigos A; Ward T; Rao AD; Lelliott EJ; Sheppard KE; Goode D; Hicks RJ; Tiganis T; Simpson KJ; Larsson O; Blythe B; Cullinane C; Wickramasinghe VO; Pearson RB; McArthur GA
    Nat Commun; 2022 Mar; 13(1):1100. PubMed ID: 35232962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
    Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
    Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
    Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal BRAF inhibition.
    Fernandez M; Sutterlüty-Fall H; Schwärzler C; Lemeille S; Boehncke WH; Merat R
    Cancer Med; 2017 Jul; 6(7):1652-1664. PubMed ID: 28573821
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Sanchez IM; Purwin TJ; Chervoneva I; Erkes DA; Nguyen MQ; Davies MA; Nathanson KL; Kemper K; Peeper DS; Aplin AE
    Mol Cancer Ther; 2019 Sep; 18(9):1637-1648. PubMed ID: 31270153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
    Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.
    Tangella LP; Clark ME; Gray ES
    Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129736. PubMed ID: 32956754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma.
    Hüser L; Sachindra S; Granados K; Federico A; Larribère L; Novak D; Umansky V; Altevogt P; Utikal J
    Int J Cancer; 2018 Dec; 143(12):3131-3142. PubMed ID: 29905375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Therapy for Melanoma.
    Wong DJ; Ribas A
    Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.
    Liu D; Liu X; Xing M
    Cell Cycle; 2014; 13(2):208-19. PubMed ID: 24200969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced expression of the RNA-binding protein HuR attenuates the adaptive response to BRAF inhibition in melanoma.
    Merat R; Bugi-Marteyn A; Wrobel LJ; Py C; Daali Y; Schwärzler C; Liaudet N
    Biochem Biophys Res Commun; 2019 Sep; 517(2):181-187. PubMed ID: 31279529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors].
    Molnár E
    Magy Onkol; 2020 Mar; 64(1):76-78. PubMed ID: 32181767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors.
    Marchetti P; Trinh A; Khamari R; Kluza J
    Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):999-1005. PubMed ID: 29413908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined BRAF and HSP90 Inhibition in Patients with Unresectable
    Eroglu Z; Chen YA; Gibney GT; Weber JS; Kudchadkar RR; Khushalani NI; Markowitz J; Brohl AS; Tetteh LF; Ramadan H; Arnone G; Li J; Zhao X; Sharma R; Darville LNF; Fang B; Smalley I; Messina JL; Koomen JM; Sondak VK; Smalley KSM
    Clin Cancer Res; 2018 Nov; 24(22):5516-5524. PubMed ID: 29674508
    [No Abstract]   [Full Text] [Related]  

  • 20. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
    Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
    PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.